AIDS

Skip Navigation LinksHome > August 22, 2006 - Volume 20 - Issue 13 > Short-term antiviral activity of TMC278 – a novel NNRTI – in...
AIDS:
doi: 10.1097/01.aids.0000242818.65215.bd
Clinical Science

Short-term antiviral activity of TMC278 – a novel NNRTI – in treatment-naive HIV-1-infected subjects

Goebel, Franka; Yakovlev, Alexyb; Pozniak, Anton Lc; Vinogradova, Elenad; Boogaerts, Griete; Hoetelmans, Richarde; de Béthune, Marie-Pierre Pe; Peeters, Monikae; Woodfall, Briane

Collapse Box

Abstract

Objective: To evaluate antiviral activity, pharmacokinetics, tolerability and safety of TMC278, a non-nucleoside reverse transcriptase inhibitor (NNRTI), when given as a 25, 50, 100 or 150 mg once-daily dose for 7 days to antiretroviral-naive HIV-infected subjects.

Design: Randomized, double-blind, placebo-controlled, phase IIa clinical trial.

Methods: Participants were 47 antiretroviral naive HIV-infected subjects. Primary outcome was the change in plasma HIV-1 RNA viral load from baseline to day 8. Secondary outcomes were evaluation of pharmacokinetics of TMC278, immunologic changes, safety and tolerability, and evolution of viral genotypic and phenotypic patterns.

Results: Patients treated with TMC278 achieved a median decrease in plasma viral load from baseline of 1.199 log10 copies/ml compared with a 0.002 log10 copies/ml gain in the placebo group (P < 0.01). A significantly higher proportion of subjects in the TMC278 groups obtained a viral load decrease of > 1.0 log10 compared with the placebo group (25/36 versus 0/11) (P < 0.01). No significant dose differences were noted in either antiviral effect or safety. No genotypic changes associated with antiretroviral resistance were detected between baseline and the end of the trial. Plasma concentrations of TMC278 were above the target concentration (13.5 ng/ml) at all time points for all TMC278-treated subjects. The most common reported adverse event was headache (TMC278 14%; placebo 18%).

Conclusions: TMC278 showed antiviral activity when given as monotherapy for 7 days at all doses studied and the drug was safe and well tolerated. Trials of longer treatment duration with TMC278, in combination with other antiretroviral drugs, are underway to assess the long-term durability of antiviral response, safety and tolerability.

© 2006 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.